NASDAQ:ITRM - Iterum Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.73 -0.02 (-0.73 %) (As of 01/23/2020 04:00 PM ET) Add Compare Today's Range$2.58Now: $2.73▼$2.7950-Day Range$2.41MA: $3.59▼$5.1852-Week Range$1.68Now: $2.73▼$9.30Volume119,752 shsAverage Volume173,350 shsMarket Capitalization$38.11 millionP/E RatioN/ADividend YieldN/ABeta2.21 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITRM Previous Symbol CUSIPN/A CIK1659323 Webhttp://www.iterumtx.com/ Phone353-1903-8920Debt Debt-to-Equity Ratio0.44 Current Ratio0.99 Quick Ratio0.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$870,000.00 Price / Sales43.80 Cash FlowN/A Price / Cash FlowN/A Book Value$5.13 per share Price / Book0.53Profitability EPS (Most Recent Fiscal Year)($7.11) Net Income$-77,060,000.00 Net MarginsN/A Return on Equity-266.00% Return on Assets-124.50%Miscellaneous Employees48 Outstanding Shares13,959,000Market Cap$38.11 million Next Earnings Date3/23/2020 (Estimated) OptionableNot Optionable Receive ITRM News and Ratings via Email Sign-up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ITRM Rates by TradingView Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions What is Iterum Therapeutics' stock symbol? Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM." How were Iterum Therapeutics' earnings last quarter? Iterum Therapeutics PLC (NASDAQ:ITRM) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($2.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.61) by $0.54. View Iterum Therapeutics' Earnings History. When is Iterum Therapeutics' next earnings date? Iterum Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Iterum Therapeutics. What price target have analysts set for ITRM? 7 analysts have issued 1 year target prices for Iterum Therapeutics' stock. Their forecasts range from $4.00 to $20.00. On average, they expect Iterum Therapeutics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 302.9% from the stock's current price. View Analyst Price Targets for Iterum Therapeutics. What is the consensus analysts' recommendation for Iterum Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Iterum Therapeutics. What are Wall Street analysts saying about Iterum Therapeutics stock? Here are some recent quotes from research analysts about Iterum Therapeutics stock: 1. According to Zacks Investment Research, "Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company's product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland. " (11/19/2019) 2. HC Wainwright analysts commented, "Valuation We employ a rNPV model, shown below, to value ITRM at $17 per share. We estimate the current risk- adjusted per-share value of sulopenem across its three indications: (1) $6.44 for cUTI (68% POS; $244M peak revenues in 2035); (2) $5.31 for uUTI (65% POS; $179M peak sales in 2035); and (3) $5.46 for cIAI (68% POS; $153M peak sales in 2035)." (6/21/2019) 3. Needham & Company LLC analysts commented, "Iterum reported 4Q18 financial results today. Mgmt reiterated guidance for top-line results from all three ongoing Phase 3 trials of sulopenem in 2H19 (complicated UTI, uncomplicated UTI, and complicated Intra- Abdominal Infections). We expect each trial to meet non-inferiority primary endpts, but acknowledge increased risk at reaching the secondary superiority endpt in the subset of patients w/ ciprofloxacin-resistant infections in the uUTI trial. Regardless, meeting primary non-inferiority endpts is sufficient for regulatory approval. The UTI market represents one of the most attractive opportunities in the antibiotic space due to absence of a sufficiently potent oral antibiotic coupled with a commercial opportunity that is large and primarily outside the hospital." (3/25/2019) Has Iterum Therapeutics been receiving favorable news coverage? Media coverage about ITRM stock has trended somewhat positive on Thursday, InfoTrie reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iterum Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Iterum Therapeutics. Are investors shorting Iterum Therapeutics? Iterum Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 336,400 shares, an increase of 21.3% from the December 15th total of 277,400 shares. Based on an average trading volume of 278,600 shares, the short-interest ratio is currently 1.2 days. Approximately 5.0% of the company's shares are short sold. View Iterum Therapeutics' Current Options Chain. Who are some of Iterum Therapeutics' key competitors? Some companies that are related to Iterum Therapeutics include Adamas Pharmaceuticals (ADMS), Galectin Therapeutics (GALT), PhaseBio Pharmaceuticals (PHAS), CannTrust (CTST), Menlo Therapeutics (MNLO), Aptinyx (APTX), TapImmune (MRKR), Sierra Oncology (SRRA), Avenue Therapeutics (ATXI), Evelo Biosciences (EVLO), Strongbridge Biopharma (SBBP), Savara (SVRA), Abeona Therapeutics (ABEO), Cassava Sciences (SAVA) and AcelRx Pharmaceuticals (ACRX). What other stocks do shareholders of Iterum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Innovate Biopharmaceuticals (INNT), Axsome Therapeutics (AXSM), Viking Therapeutics (VKTX), Aeglea Bio Therapeutics (AGLE), Ninetowns Internet Technlgy Grp (NINE), Intellia Therapeutics (NTLA), Rigel Pharmaceuticals (RIGL), Barkerville Gold Mines (BGM), Melinta Therapeutics (MLNT) and Puma Biotechnology (PBYI). Who are Iterum Therapeutics' key executives? Iterum Therapeutics' management team includes the folowing people: Mr. Corey N. Fishman, Pres, CEO & Director (Age 54)Ms. Judith M. Matthews, Chief Financial Officer (Age 49)Dr. Michael W. Dunne, Chief Scientific Officer (Age 59)Mr. Benjamin M. Pe, VP of Operations When did Iterum Therapeutics IPO? (ITRM) raised $80 million in an IPO on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. How do I buy shares of Iterum Therapeutics? Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Iterum Therapeutics' stock price today? One share of ITRM stock can currently be purchased for approximately $2.73. How big of a company is Iterum Therapeutics? Iterum Therapeutics has a market capitalization of $38.11 million and generates $870,000.00 in revenue each year. The company earns $-77,060,000.00 in net income (profit) each year or ($7.11) on an earnings per share basis. Iterum Therapeutics employs 48 workers across the globe.View Additional Information About Iterum Therapeutics. What is Iterum Therapeutics' official website? The official website for Iterum Therapeutics is http://www.iterumtx.com/. How can I contact Iterum Therapeutics? Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at 353-1903-8920 or via email at [email protected] MarketBeat Community Rating for Iterum Therapeutics (NASDAQ ITRM)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 100 (Vote Outperform)Underperform Votes: 111 (Vote Underperform)Total Votes: 211MarketBeat's community ratings are surveys of what our community members think about Iterum Therapeutics and other stocks. Vote "Outperform" if you believe ITRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITRM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2020 by MarketBeat.com StaffFeatured Article: What is Forex?
